Australia
Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company. The company's lead asset, bisantrene, has demonstrated therapeutic benefits in both adult and pediatric patients and possesses a well-characterized safety profile. Race Oncology is advancing a reformulated bisantrene (RC220) to address the unmet needs of patients across multiple oncology indications, particularly focusing on anthracycline combinations to deliver cardioprotection and enhanced anti-cancer activity in solid tumors. Additionally, the company is exploring RC220 as a low-intensity treatment for acute myeloid leukemia. Moreover, Race Oncology is investigating the effect of bisantrene on the m6A RNA pathway, following independent research identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein), a driver of a diverse range of cancers.
The company has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle and is actively exploring partnerships, license agreements or commercial merger and acquisitions to accelerate access to bisantrene for cancer patients worldwide. As a clinical stage biopharmaceutical company, Race Oncology, founded in 2016, is positioned to make a significant impact in the pharmaceutical industry with its innovative approach to cancer care.
